Molecular diagnostics company, Inflammatix, disclosed on Tuesday that Kian Beyzavi, PhD has been appointed as an independent member of its board of directors.

The company said that Dr Beyzavi has over 25 years of experience as a venture investor, entrepreneur, consultant, and general manager in the healthcare industry, with significant operating experience in the medical device and diagnostics industries, and a focus on leveraging innovative technologies to improve diagnosis and delivery of care.

Dr Beyzavi started her career at McKinsey & Company and has also worked for Rho Ventures, Cubit Software, Medtronic, Abbott Diabetes Care and Novartis Diagnostics.

Over the past 10 years, Dr Beyzavi has led a specialized consulting firm advising Fortune 500 companies, startups and others in the areas of strategy, product development, business model innovation, commercialization, and monetization of novel opportunities across life sciences.

Currently, Dr Beyzavi a venture partner at Cota Capital, a multistage investment firm.

Inflammatix is focused on acute infections and sepsis, where its tests combine proprietary biomarkers and advanced machine learning to help physicians quickly get the right treatments to the right patients. It added that future tests will be developed to run on the company's sample-to-answer isothermal instrument platform in under 30 minutes.

Based in Burlingame, CA, the company is funded by medical technology investors that include Khosla Ventures, Northpond Ventures, D1 Capital Partners, Think.Health Ventures and others.